mobile-logo

All

20 Jan

Precision Medicine = Precision Targeting

by Marianne Ryan
in All
Comments

The future of medicine is being driven by technology as a part of scientific discovery. Precision medicine, an emerging treatment paradigm, aims to find the right therapy at the right time based on an individual's unique genetic background,. Studies of phenotypes and genotypes, along with the use of Artificial Intelligence (AI), have provided vast and expanding knowledge of how genomics play a role in determining...

Read More
19 Nov

Using Data to Improve Minority Trial Recruitment

by Marianne Ryan
in All, Healthcare Data Management, Industry News, Life Sciences, Technology
Comments

A recent news headline by Reuters: “Modern vaccine trial contractors fail to enroll enough minorities, prompting slowdown”   The COVID-19 pandemic has shed new light on a decades-old problem related to recruitment in clinical trials: under-enrollment among racial and ethnic minorities.  In order to truly understand the efficacy and safety of new medicines, including COVID-19 vaccines and therapies, as well as generalize research findings, a cross-section of...

Read More
09 Sep

Using State-of-the-Art Technology to Assess the Impact of COVID-19?

by Marianne Ryan
in All, Healthcare Data Management, Industry News, Innovation, Technology
Comments

Pharma is facing the many challenges of COVID-19 head-on. Leading organizations are taking full advantage of today’s sophisticated analytic tools, including state-of-the-art anonymization technologies that seamlessly link patient data across multiple sources, to monitor the impact of COVID-19 on treatments in new ways.   Since the COVID-19 pandemic began, the industry has been primarily focused on understanding the journey of severely ill, older adults requiring hospitalization. More...

Read More
31 Jul

COVID-19 Impact on Recovered Patients with Chronic Diseases

by Marianne Ryan
in All, Industry News, Technology
Comments

A close examination of the COVID-19 patient journey will result in a better understanding of the impact of the virus on at-risk diabetes patients. Segmenting positive and negative COVID-19 patients provides a real world comparison of anonymized patient cohorts’ A1C, fasting blood sugars, and glucose levels. Linked with prescribed medications, this data will identify the impact of COVID-19 on the patients’ prescribed drug therapy. The...

Read More
MENU